Sanjeev Narula - 06 Oct 2026 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Reporting relationship: Chief Financial & Bus. Officer
Issuer ticker: PHAT
Reported as of: 06 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Oct 2026, 17:44:35 UTC
Prior SEC filing: 02 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Breedlove, Attorney-in-Fact for Sanjeev Narula

Key filing fact

Sanjeev Narula filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 08 Oct 2026.

Key facts

This page summarizes Sanjeev Narula's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Oct 2026, 17:44.

Change

Previous filing in this sequence was filed on 02 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001820590 Primary reporting owner

Narula Sanjeev

Relationship: Chief Financial & Bus. Officer
Address: C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK
Signature: /s/ Robert Breedlove, Attorney-in-Fact for Sanjeev Narula
Signature date: 08 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHAT transaction

Common Stock

Tax liability

Transaction value
Shares: -13,485
Change %: -5.9%
Price: $6.78^*
Shares after: 214,718
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F1, F2

PHAT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,123
Date: 06 Oct 2026
Ownership: By 401(k)

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.

Footnote F2

Includes 1,488 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2026.